General
Preferred name
PACLITAXEL
Synonyms
BMS-181339-01 ()
Taxol ()
CHEMBL428647 ()
NSC 125973 ()
Paclitaxel (Taxol) ()
7 epi Taxol ()
7-epi-Taxol ()
Bris Taxol ()
NSC125973 ()
Praxel ()
Anzatax ()
Taxol (Registered Trademark) ()
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv. ()
Benzenepropanoic acid, .beta.-(benzoylamino)- .alpha.-hydroxy-, 6,12b-bis(acetyl oxy)-12-(benzoyloxy)- 2a,3,4,4a,5,6,9,10,11,12,12a,12b,- dodecahydro-4,11- dihydroxy-4a,8,13,13-tetramethyl-5-oxo- 7,11-methano- 1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR- [2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(alpha. R*,.beta.S*),11.alpha.,12.alpha.,12a.alpha.,12b.alpha.]]- ()
Tax-11-en-9-one, 5.beta.,20-epoxy-1,2.alpha.,4,7.beta., 10.beta.,13.alpha.- hexahydroxy-, 4,10-diacetate 2- benzoate,13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine ()
paclitaxel, Shanghai Fudan-Zhangjiang ()
Paclitaxel-d5 ()
BMS 181339-01 ()
Paclitaxel (taxus canadensis) ()
Mitotax ()
Taxol 100 ()
Tocosol paclitaxel ()
PACLITAXOL ()
Plaxicel ()
Genetaxyl ()
ABI-007 ()
Genexol ()
Oncogel ()
QW-8184 ()
Pacitaxel ()
Taxus ()
(-)-paclitaxel ()
Ebetaxel ()
Pacliex ()
MBT-0206 ()
Apealea ()
DHP 107 ()
Onxol ()
NK 105 ()
Empac ()
ABI-007 COMPONENT PACLITAXEL ()
Taxus stent ()
Genexol-pm ()
Abraxane ()
Taxol A ()
MBT 0206 ()
Paxene ()
Intaxel ()
NSC-125973 ()
DHP-107 ()
Yewtaxan ()
Taxus liberte ()
Lep-etu ()
Endotag 1 ()
Cyclopax ()
Taxalbin ()
NK-105 ()
Capxol ()
Genaxol ()
Onxal ()
P&D ID
PD004086
CAS
33069-62-4
1203669-79-7
1129540-33-5
Tags
natural product
drug
probe
nuisance
available
Approved by
PMDA
FDA
EMA
First approval
1992
Drug indication
Breast cancer
Antineoplastic
Ovarian cancer
Gastric adenocarcinoma
Pancreatic cancer
Solid tumour/cancer
Drug Status
withdrawn
approved
vet_approved
Max Phase
4.0
Probe info
Probe type
experimental probe
calculated probe
Probe sources
Chemical Probes.org
High-quality chemical probes
Tool Compound Set
Probe targets
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Paclitaxel is a tubulin inhibitor. It was originally identified and isolated from the bark of the Pacific yew, Taxus brevifolia (hence the name 'taxol', and naming of the taxane family of compounds- includes and ). The drug can be administered as a solvent-based drug, or in a formulation called nab-paclitaxel. Nab-paclitaxel consists of paclitaxel bound to albumin nanoparticles as a delivery vehicle (trade name Abraxane)- nab stands for nanoparticle albumin-bound. (GtoPdb)
MOA Stabilizes nonfunctional microtubules
MOA Inhibitor (Chemical Probes.org)
Cell lines
579
Organisms
5
Compound Sets
35
AdooQ Bioactive Compound Library
A10689
Cayman Chemical Bioactives
10461
22092
ChEMBL Approved Drugs
CHEMBL428647
ChEMBL Drugs
CHEMBL428647
Chemical Probes.org
taxol
Concise Guide to Pharmacology 2017/18
2770
Concise Guide to Pharmacology 2019/20
2770
Concise Guide to Pharmacology 2021/22
2770
Concise Guide to Pharmacology 2023/24
2770
Drug Repurposing Hub
DrugBank
DB01229
DrugBank Approved Drugs
DB01229
DrugCentral
2044
DrugCentral Approved Drugs
2044
DrugMAP
DMLB81S
DMUOT9V
DrugMAP Approved Drugs
DMLB81S
DMUOT9V
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101711
Guide to Pharmacology
2770
High-quality chemical probes
PD004086
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL428647
Mcule NIBR MoA Box Subset
MCULE-8202174308
MedChem Express Bioactive Compound Library
HY-B0015
NCATS Inxight Approved Drugs
P88XT4IS4D
NIH Approved Oncology Drugs
418145
Novartis Chemogenetic Library (NIBR MoA Box)
Nuisance compounds in cellular assays
NURSA ligand set
nursa/index.jsf?doi=10.1621%2FZJSTGVJ65V
Prestwick Chemical Library
Reference compounds for characterizing cellular injury in high-content cellular morphology assays
ReFrame library
TargetMol Bioactive Compound Library
T0968
Tool Compound Set
Welcome Trust Cancer Drugs
11
Withdrawn 2.0
EMA31
External IDs
71
Properties
(calculated by RDKit )
Molecular Weight
853.33
Hydrogen Bond Acceptors
14
Hydrogen Bond Donors
4
Rotatable Bonds
10
Ring Count
7
Aromatic Ring Count
3
cLogP
3.74
TPSA
221.29
Fraction CSP3
0.45
Chiral centers
11.0
Largest ring
8.0
QED
0.13
Structural alerts
1
Tubulin modulation
Nuisance compounds in cellular assays
Related compounds
Custom attributes
(extracted from source data)
Target
Tubulin beta-3 chain
Beta subunit of Tubulin
Microtubule
BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBA1A, TUBA1B, TUBA1C, TUBA3C, TUBA3D, TUBA3E, TUBA4A, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8
Beta-Tubulin
ADC Cytotoxin
Microtubule/Tubulin
TUBB
Pathway
cytoskeleton
Cytoskeletal Signaling
Antibody-drug Conjugate/ADC Related
Apoptosis
Autophagy
Cell Cycle/DNA Damage
Member status
member
MOA
Microtubule stabilizer
tubulin polymerization inhibitor
Indication
ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC)
Cellular injury category
Cytoskeletal
ATC
L01CD01
Target subclass
Cytoskeleton
GTPase
Target class
Structural protein
Enzyme
Therapeutic Class
Anticancer Agents
Source data